Vaxcyte director Heath Lukatch retires; John Markels appointed to board

Vaxcyte, Inc.

Heath Lukatch retired from Vaxcyte board effective July 16, 2026; no disagreement with company.
John Markels appointed as Class II director, term expiring at 2028 annual meeting.
Markels will serve on Audit and Compensation committees; qualifies as independent under Nasdaq rules.
Markels receives standard non-employee director compensation; annual equity grant currently $430,000.
No transactions or arrangements between Markels and company requiring disclosure under Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Heath Lukatch

Director

PCVX · Vaxcyte, Inc.

Effective: 2026-07-16
Successor: John Markels
Filed: July 15, 2026, 4:05 PM ET

On July 13, 2026, Heath Lukatch notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of July 16, 2026.

Appointed

John Markels

Director

PCVX · Vaxcyte, Inc.

Effective: 2026-07-16
Filed: July 15, 2026, 4:05 PM ET

Concurrently, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed John Markels to the Board as a Class II director, effective as of July 16, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Heath Lukatch retired as Director at Vaxcyte, Inc..

Action: retired
Role: Director

Exact text from the filing

On July 13, 2026, Heath Lukatch notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of July 16, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Markels was appointed as Director at Vaxcyte, Inc..

Action: appointed
Role: Director

Exact text from the filing

Concurrently, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed John Markels to the Board as a Class II director, effective as of July 16, 2026.

View on SEC.gov

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0001649094-26-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.